Zevra Therapeutics (ZVRA) FDA Announcement summary

Introduction and purpose

• FDA approved MIPLYFFA (arimoclomol) for use with miglustat to treat neurological manifestations of Niemann-Pick disease type C (NPC) in patients aged two and older.

• The approval marks a significant milestone for the NPC community, offering the first FDA-approved treatment for this ultra-rare, progressive neurodegenerative disorder.

• Zevra Therapeutics received a rare pediatric disease priority review voucher with this approval.

• NPC affects about 900 people in the U.S.

Details of approval or decision

• MIPLYFFA is indicated for combination use with miglustat in both adult and pediatric patients aged two and older.

• Approval is based on data from a 12-month, multicenter, randomized, double-blind, placebo-controlled trial and a 48-month open-label extension study, including FDA-preferred analyses.

• Zevra will launch MIPLYFFA in the U.S. within eight to twelve weeks and has introduced the AmplifyAssist patient support program.

Impact on industry and stakeholders

• The approval is expected to remove historical access barriers and establish MIPLYFFA as the cornerstone of NPC therapy.

• AmplifyAssist program offers insurance, copay, therapy management, and prescription support for eligible patients and caregivers.

• Healthcare providers can access prescription enrollment and support resources online.

• Approximately 80% of diagnosed NPC patients are already treated with miglustat, and payers have indicated willingness to cover the combination.